Condition

PCOS, insulin resistance, and the metabolic side of the diagnosis

Polycystic ovary syndrome is as much a metabolic condition as a reproductive one. For many women, treating insulin resistance is the lever that moves cycle regularity, fertility, and weight at the same time.

How PCOS is diagnosed

The most widely used framework is the Rotterdam criteria. Diagnosis requires at least two of:

Oligo- or anovulation — irregular or absent periods.
Clinical or biochemical hyperandrogenism — hirsutism, acne, scalp hair thinning, or elevated total/free testosterone.
Polycystic ovarian morphology on ultrasound — 20+ follicles in either ovary or ovarian volume ≥10 mL.

Other causes (thyroid disease, hyperprolactinemia, nonclassic congenital adrenal hyperplasia, Cushing's) need to be ruled out. The 2023 international PCOS guideline made ultrasound optional when the other two criteria are clearly met.

The metabolic axis behind the diagnosis

An estimated 60–80% of women with PCOS have insulin resistance, independent of body weight. High insulin levels:

Stimulate the ovaries to produce more androgens (testosterone), driving acne, hirsutism, and hair loss.
Suppress sex hormone-binding globulin (SHBG), increasing the fraction of free testosterone in circulation.
Disrupt the LH:FSH ratio and ovulatory signaling.
Promote visceral fat deposition, which feeds back to worsen insulin resistance.

This is why interventions that lower insulin levels — weight loss, metformin, GLP-1 medications — frequently improve cycle regularity, androgen symptoms, and fertility together.

Why weight loss is leveraged so often

Even modest weight loss (5–10% of body weight) in women with PCOS and overweight/obesity has been shown to:

Restore ovulation in 30–50% of women.
Reduce circulating androgens.
Improve glucose tolerance and lower diabetes risk.
Improve pregnancy rates among those trying to conceive.

The challenge: PCOS itself appears to make weight loss harder. Higher insulin levels favor fat storage, satiety signaling is often blunted, and resting metabolic rate may be slightly lower. This is the rationale for adding pharmacotherapy when lifestyle alone has plateaued.

GLP-1 medications in PCOS — what the evidence shows

Evidence for GLP-1 receptor agonists in PCOS is rapidly expanding. Recent randomized trials and meta-analyses report:

Significant reductions in body weight and waist circumference vs. placebo or metformin alone.
Improved menstrual regularity in 50–80% of treated women.
Reductions in fasting insulin and HOMA-IR (a measure of insulin resistance).
Modest reductions in free androgen index.

Important fertility note: GLP-1 medications are not recommended during pregnancy or while actively trying to conceive, and should be stopped at least 2 months before attempting pregnancy. Because GLP-1 therapy can restore ovulation, reliable contraception is essential during treatment if pregnancy is not desired.

Treatment combinations clinicians use

Goal	Common combinations
Cycle regularity, no fertility goal	Combined oral contraceptive + lifestyle ± metformin
Androgen symptoms (acne, hirsutism)	Combined OCP + spironolactone + topical care
Insulin resistance + overweight/obesity	Lifestyle + metformin + GLP-1 receptor agonist
Trying to conceive	Letrozole ± metformin (GLP-1s discontinued before TTC)

WeightlessRx focuses on the metabolic and weight-management side of PCOS. We coordinate with each patient's gynecologist or reproductive endocrinologist for cycle, fertility, and androgen-specific therapies.

Long-term health considerations

Women with PCOS carry elevated lifetime risk for:

Type 2 diabetes (3–7x baseline risk; consider screening every 1–3 years).
Metabolic syndrome and fatty liver disease.
Cardiovascular disease.
Endometrial hyperplasia and endometrial cancer (from chronic anovulation).
Depression, anxiety, and disordered eating — at meaningfully higher rates than peers.

Treating insulin resistance early — and supporting mental health throughout — measurably reduces these long-term risks.

Frequently asked questions

What is PCOS?

Polycystic ovary syndrome is a common endocrine disorder of reproductive-age women defined by some combination of irregular ovulation, elevated androgens, and polycystic-appearing ovaries. It is closely linked to insulin resistance and increases the lifetime risk of type 2 diabetes and cardiovascular disease.

Can GLP-1 medications help PCOS?

Yes, particularly for women with PCOS who also have overweight or obesity. Trials show that GLP-1 receptor agonists like semaglutide and tirzepatide reduce weight, lower insulin and androgen levels, and improve menstrual regularity — often more effectively than metformin alone.

Do I have to have overweight/obesity to qualify for GLP-1 therapy?

WeightlessRx generally requires BMI 27 or higher with at least one weight-related condition (PCOS qualifies), or BMI 30 or higher without complications. Lean PCOS is best managed with metformin, lifestyle, and gynecologic therapies.

Will GLP-1s help me get pregnant?

By improving insulin sensitivity and weight, GLP-1s often restore ovulation, which can improve fertility. However, GLP-1s themselves are not safe during pregnancy and should be stopped at least 2 months before trying to conceive. Use reliable contraception while on therapy if pregnancy is not desired.

Is metformin still useful?

Yes. Metformin remains a first-line option for insulin resistance in PCOS and is often combined with GLP-1 therapy. It is also safer to continue if pregnancy is being attempted.

Will birth control still be needed on a GLP-1?

Often yes — particularly if cycle regulation, acne, and androgen symptoms are also goals. GLP-1s do not replace combined oral contraceptives or spironolactone for those targets.

Can teens with PCOS use GLP-1s?

Liraglutide and semaglutide are approved for adolescents 12+ for obesity. Use in adolescents with PCOS specifically is emerging and should be coordinated with a pediatric endocrinologist or adolescent gynecologist.

Does PCOS go away?

PCOS persists across the reproductive years, but symptoms can be substantially controlled and metabolic risk reduced. After menopause many features (hyperandrogenism, irregular cycles) attenuate, though metabolic risks remain elevated.

See if you qualify with WeightlessRx

U.S.-licensed clinicians review every intake. Direct-pay membership — medication, support, and shipping included.

Choose a plan

References

Teede HJ et al. International evidence-based guideline for PCOS, 2023.
Legro RS et al. Obesity, weight loss, and PCOS treatment outcomes. JCEM 2016.
Jensterle M et al. Liraglutide vs. metformin in PCOS — randomized trial. Endocrine 2020.
Cena H et al. Obesity, polycystic ovary syndrome, and infertility. Nutrients 2020.
Bednarz K et al. The role of GLP-1 receptor agonists in PCOS — systematic review. Front Endocrinol 2022.
Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited. Endocr Rev 2012;33:981–1030.

Editorial standards

Reviewed against current GLP-1 prescribing labeling, ADA Standards of Care, AACE/Endocrine Society guidelines, and peer-reviewed clinical literature. Educational content — not a substitute for individualized medical advice. See our medical review policy.